Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Polymer Implant Delivers Drugs to Pancreatic Tumors

By HospiMedica International staff writers
Posted on 28 Apr 2016
A novel implantable delivery platform can provide local chemotherapy for treating pancreatic ductal adenocarcinoma (PDAC), according to a new study.

Developed by researchers at the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) and Massachusetts General Hospital (MGH; Boston, MA, USA), the implant is a biodegradable polymer flexible film made of poly lactic-co-glycolic acid (PLGA), and is designed to release high doses of chemotherapeutic drugs for up to 60 days. More...
For delivery, the film is rolled into a tube and inserted through a catheter; once it reaches the pancreas, it unfolds and conforms to the shape of the tumor, releasing the embedded drugs only from the tumor-facing side to reduce side effects.

To compare the device's efficacy to that of traditional chemotherapy, a study was conducted in mice carrying human pancreatic tumors. One group of mice was treated with the implant carrying the chemo drug paclitaxel, while the other group received injections of the same drug for four weeks, simulating current treatment for human patients. The results showed that tumor growth slowed in mice with the implant; in some cases, the tumors even shrank. After four weeks, the implant group showed five times the paclitaxel concentration in their tumors that the intravenous group did.

In addition to successfully delivering the drug to the pancreas, the researchers also observed other positive effects. The localized treatment increased the amount of necrotic tissue, and since there are few blood vessels in pancreatic tumors, the paclitaxel tended to remain in-situ, preventing toxic effects in healthy tissues. Additionally, by acting as a physical barrier, the film was able to reduce metastasis to nearby organs. The study describing the implant and the murine study was published early online on March 31, 2016, in Biomaterials.

“The greatest benefit of this device is the ability to implant it with minimally invasive procedures, so we can give a tool to oncologists and surgeons to reach tumors that otherwise would be difficult to reach,” said lead author Laura Indolfi, PhD, of the MIT Institute for Medical Engineering and Science (IMES) and the MGH Cancer Center. “You can implant our device to achieve a localized drug release to control tumor progression and potentially shrink the tumor to a size where a surgeon can remove it.”

Pancreatic cancer patients often suffer from blockage of the bile duct, which interferes with digestion and is very painful. The duct can be reopened with a stent, but usually gets blocked again, requiring the patient to have the old stent removed and a new one inserted. According to the researchers, the film could also be used as a coating for such a stent, helping to prevent the cancer cells from spreading into the bile duct and blocking it again.

Related Links:
Massachusetts Institute of Technology
Massachusetts General Hospital

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.